# Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

Article · Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A

- Archive id: doi:10.1007/s00125-017-4289-0
- Published: 2017-05-19
- Venue: Diabetologia
- DOI: https://doi.org/10.1007/s00125-017-4289-0
- PMID: 28526920
- PMCID: PMC5491562
- Citations: 97
- Source URL: https://doi.org/10.1007/s00125-017-4289-0
- PDF: https://europepmc.org/articles/PMC5491562/pdf
- Provenance: europepmc

## Abstract

Aims/hypothesis Semaglutide is a glucagon-like peptide-1 analogue in development for the treatment of type 2 diabetes. Its effects on first- and second-phase insulin secretion and other measures of beta cell function and glycaemic control were assessed. Methods In this single-centre, double-blind, placebo-controlled, parallel-group trial, conducted at the Profil Institut für Stoffwechselforschung, Germany, 75 adult (aged 18-64 years) participants with type 2 diabetes (eligibility: HbA 1c of 6.5-9.0% (47.5-74.9 mmol/mol); BMI 20.0-35.0 kg/m 2 ; and treatment with diet and exercise and/or metformin monotherapy with a dose unchanged in the 30 days prior to screening) were randomised (1:1) to once-weekly s.c. semaglutide 1.0 mg (0.25, 0.5, 1.0 mg escalated) or placebo for 12 weeks. Co-primary endpoints were changes from baseline to end of treatment in the first (AUC 0-10 min ) and second (AUC 10-120 min ) insulin secretion phases, as measured by the IVGTT. An arginine stimulation test (AST) and a 24 h meal stimulation test were also conducted. A graded glucose infusion test (GGIT) assessed insulin secretion rate (ISR) in treated participants and a group of untreated healthy participants. Safety endpoints were also assessed. Results In total, 37 participants received semaglutide and 38 received placebo. Following IVGTT, for insulin, both AUC 0-10min and AUC 10-120min were significantly increased with semaglutide (estimated treatment ratio \[95% CI\] 3.02 \[2.53, 3.60\] and 2.10 \[1.86, 2.37\], respectively; p \< 0.0001). The 24 h meal test showed reduced fasting, postprandial and overall (AUC 0-24h ) glucose and glucagon responses with semaglutide (p \< 0.0001). The AST showed that maximal insulin capacity increased following semaglutide treatment. During GGIT, semaglutide significantly increased ISR to levels similar to those in healthy participants. Semaglutide was well tolerated. Conclusions/interpretation Twelve weeks of once-weekly treatment with semaglutide significantly improved beta cell function and glycaemic control in participants with type 2 diabetes. Trial registration ClinicalTrials.gov NCT02212067 FUNDING: The study was funded by Novo Nordisk A/S.

_Abstract reproduced under CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.